UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

British journal of cancer, 2016-11, Vol.115 (10), p.1157-1173

2016

Volltextzugriff (PDF)

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1796-1804

2012

Volltextzugriff (PDF)

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 2014-10, Vol.106 (10), p.1

2014

Volltextzugriff (PDF)

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Journal of clinical oncology, 2011-09, Vol.29 (25), p.3351-3357

2011

Volltextzugriff (PDF)

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1630-1639

2006

Volltextzugriff (PDF)

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Clinical cancer research, 2011-03, Vol.17 (6), p.1591-1602

2011

Volltextzugriff (PDF)

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (10), p.739-749

2004

Volltextzugriff (PDF)

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

The lancet oncology, 2015-06, Vol.16 (6), p.686-694

2015

Volltextzugriff (PDF)

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

Journal of clinical oncology, 2010-06, Vol.28 (17), p.2874-2880

2010

Volltextzugriff (PDF)

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Clinical cancer research, 2011-04, Vol.17 (8), p.2373-2384

2011

Volltextzugriff (PDF)

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

Scientific reports, 2014-02, Vol.4 (1), p.4026-4026, Article 4026

2014

Volltextzugriff (PDF)

Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer

The lancet oncology, 2019-05, Vol.20 (5), p.612-614

Konecny, Gottfried E

2019

Volltextzugriff (PDF)

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures

Gynecologic oncology, 2016-04, Vol.141 (1), p.95-100

2016

Volltextzugriff (PDF)

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Gynecologic oncology reports, 2023-06, Vol.47, p.101155-101155, Article 101155

2023

Volltextzugriff (PDF)

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

Diagnostic pathology, 2022-09, Vol.17 (1), p.70-70, Article 70

2022

Volltextzugriff (PDF)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

British journal of cancer, 2009-11, Vol.101 (10), p.1699-1708

2009

Volltextzugriff (PDF)

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

International journal of molecular sciences, 2013-02, Vol.14 (2), p.3094-3109

2013

Volltextzugriff (PDF)

Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer

Journal of clinical oncology, 2009-06, Vol.27 (18), p.2938-2945

2009

Volltextzugriff (PDF)

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

Molecular cancer therapeutics, 2013-05, Vol.12 (5), p.632-642

2013

Volltextzugriff (PDF)

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

British journal of cancer, 2009-01, Vol.100 (1), p.89-95

2009

Volltextzugriff (PDF)

Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Clinical cancer research, 2004-03, Vol.10 (5), p.1706-1716

2004

Volltextzugriff (PDF)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

British journal of cancer, 2008-03, Vol.98 (6), p.1076-1084

2008

Volltextzugriff (PDF)

1 – 25 von 499

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(412)
Mit Volltextzugriff
(383)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer—results at the time of surgery

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

Suchergebnisse filtern